About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker SPRO · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Mar 10, 2026A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilast…
NCT06059846 · Urinary Tract Infection, Acute Pyelonephritis
TBP-PI-HBr, Imipenem-cilastatin
SPRO
Spero Therapeutics
Phase 3Completed1,690Jan 27, 2025Registry ↗
Oct 9, 2025A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared…
NCT05496374 · Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
Placebo, SPR720 500 mg
SPRO
Spero Therapeutics
Phase 2Completed25Oct 8, 2024Registry ↗
May 20, 2025A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (…
NCT06727136 · Healthy Participants
TBP-PI-HBr
SPRO
Spero Therapeutics
Phase 1Completed39Apr 22, 2025Registry ↗
Apr 15, 2024Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function
NCT04865393 · Renal Impairment
SPR206
SPRO
Spero Therapeutics
Phase 1Completed37Dec 1, 2021Registry ↗
Mar 27, 2024A Study to Compare Two Bioanalytical Assays for Tebipenem
NCT05856747 · Healthy Volunteers
TBP-PI-HBr
SPRO
Spero Therapeutics
Phase 1Completed20Jun 1, 2023Registry ↗
Mar 7, 2024A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epith…
NCT05955586 · Healthy Volunteer
SPR720
SPRO
Spero Therapeutics
Phase 1Completed33Feb 9, 2024Registry ↗
Mar 4, 2024A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin…
NCT05966688 · Healthy Volunteers
SPR720, Azithromycin
SPRO
Spero Therapeutics
Phase 1Completed39Jan 30, 2024Registry ↗
Jul 25, 2022Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil…
NCT03788967 · Complicated Urinary Tract Infection, Acute Pyelonephritis
TBPM-PI-HBr, Ertapenem
SPRO
Spero Therapeutics
Phase 3Completed1,372May 20, 2020Registry ↗
Feb 28, 2022Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With My…
NCT04553406 · Mycobacterium Avium Complex, Non-tuberculous Mycobacterium…
SPR720, Placebo
SPRO
Spero Therapeutics
Phase 2Terminated2Jan 28, 2021Registry ↗
Nov 17, 2021Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers
NCT04868292 · Healthy Volunteers
SPR206
SPRO
Spero Therapeutics
Phase 1Completed34Sep 16, 2021Registry ↗
May 4, 2021Effect of Tebipenem on Normal Human Intestinal Microbiota
NCT04376554 · Healthy Volunteers
TBPM-PI-HBr, amoxicillin-clavulanate
SPRO
Spero Therapeutics
Phase 1Completed30Apr 6, 2021Registry ↗
Mar 16, 2021Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial L…
NCT04710407 · Healthy Volunteers
TBPM-PI-HBr
SPRO
Spero Therapeutics
Phase 1Completed30Mar 10, 2021Registry ↗
Nov 27, 2020Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Var…
NCT04178577 · Renal Impairment
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
SPRO
Spero Therapeutics
Phase 1Completed39Sep 6, 2020Registry ↗
Nov 12, 2020Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI…
NCT04625855 · Healthy Volunteers
TBPM-PI-HBr
SPRO
Spero Therapeutics
Phase 1Completed8Oct 16, 2020Registry ↗
Sep 4, 2020Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipe…
NCT04368585 · Healthy Volunteers
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr), 20 mL aluminu…
SPRO
Spero Therapeutics
Phase 1Completed20Aug 8, 2020Registry ↗
Aug 12, 2020Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-H…
NCT04421885 · Healthy Volunteers
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference, T…
SPRO
Spero Therapeutics
Phase 1Completed36Jul 11, 2020Registry ↗
Mar 13, 2020A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluati…
NCT04238195 · TQT Study
Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo, Mox…
SPRO
Spero Therapeutics
Phase 1Completed24Feb 26, 2020Registry ↗
Jan 10, 2020A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Hea…
NCT03792308 · Healthy Volunteers
SPR206, Placebo
SPRO
Spero Therapeutics
Phase 1Completed94Dec 23, 2019Registry ↗
Oct 28, 2019A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers
NCT03796910 · Healthy Volunteers
SPR720 for SAD, Placebo for SAD
SPRO
Spero Therapeutics
Phase 1Completed96Sep 24, 2019Registry ↗
Aug 28, 2018Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994
NCT03395249 · Healthy Volunteers
SPR994, Placebo Oral Tablet
SPRO
Spero Therapeutics
Phase 1Completed124Aug 2, 2018Registry ↗
Jan 5, 2018Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741
NCT03376529 · Healthy Volunteers
SPR741, Ceftazidime
SPRO
Spero Therapeutics
Phase 1Completed27Dec 19, 2017Registry ↗
Oct 5, 2017A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Hea…
NCT03022175 · Healthy Volunteers
SPR741, Placebo
SPRO
Spero Therapeutics
Phase 1Completed64Jul 2017Registry ↗

22 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:24 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances